XENOX - Evaluation of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin + 5-FU/LV Chemotherapy

Inclusion Criteria

• •Histologically or cytologically proven adenocarcinoma of the colon or the rectum
• •age \> 18 years
• •WHO performance status : 0,1,2
• •Signed written informed consent prior to study entry
• •Disease stage : metastatic disease not amenable to potentially curative treatment (eg : inoperable metastatic disease)
• •Measurable disease
• •No prior chemotherapeutic regimen for metastatic disease ; prior adjuvant chemotherapy allowed (disease free interval from end of adjuvant therapy of at least 6 months)
• •Prior radiotherapy permitted, if completed at least 3 weeks before randomization, and if not administered to target lesions identified for the study